Christos Chatzikyrkou1, Roland E Schmieder2, Mario Schiffer2. 1. Medical Faculty, Otto-von Guericke University Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany. chatziky@gmx.de. 2. Department of Internal Medicine 4-Nephrology, University Hospital of Erlangen, Erlangen, Germany.
Abstract
PURPOSE OF REVIEW: To incorporate novel findings on pathophysiology and treatment of posttransplant hypertension. RECENT FINDINGS: (1) The sodium retaining effects of CNIs are mediated by stimulation of the thiazide-sensitive sodium chloride co-transporter in the distal convoluted tubule and in this regard chlorthalidone was proven to be an effective antihypertensive drug in renal transplantation. (2) Local and not systemic activation of the renin-angiotensin-aldosterone system plays a crucial role in the pathogenesis of posttransplant hypertension. (3) Recent randomized controlled trials failed to prove the presumed superiority of renin-angiotensin blockers in kidney transplantation. (4) Steroid-free and mammalian target of rapamycin-based immunosuppressive drug combinations did not show favorable effects on blood pressure control. (5) In a recent report the risk of non-melanoma skin cancer was higher with thiazide diuretics. But the increased cancer risk in transplant recipients is mainly attributed to comorbidities, such as diabetes and hypertension and of course to the transplantation condition itself or the obligatory application of immunosuppression, and has little to do with the antihypertensive medication Actual recommendations about BP targets in adult renal transplant recipients are coming from a post hoc analysis of a large randomized trial with another primary endpoint. Unless convincing studies on treatment of hypertension after renal transplantation are available, the ESC/ESH Guidelines 2018 should apply for these patients.
PURPOSE OF REVIEW: To incorporate novel findings on pathophysiology and treatment of posttransplant hypertension. RECENT FINDINGS: (1) The sodium retaining effects of CNIs are mediated by stimulation of the thiazide-sensitive sodium chloride co-transporter in the distal convoluted tubule and in this regard chlorthalidone was proven to be an effective antihypertensive drug in renal transplantation. (2) Local and not systemic activation of the renin-angiotensin-aldosterone system plays a crucial role in the pathogenesis of posttransplant hypertension. (3) Recent randomized controlled trials failed to prove the presumed superiority of renin-angiotensin blockers in kidney transplantation. (4) Steroid-free and mammalian target of rapamycin-based immunosuppressive drug combinations did not show favorable effects on blood pressure control. (5) In a recent report the risk of non-melanoma skin cancer was higher with thiazide diuretics. But the increased cancer risk in transplant recipients is mainly attributed to comorbidities, such as diabetes and hypertension and of course to the transplantation condition itself or the obligatory application of immunosuppression, and has little to do with the antihypertensive medication Actual recommendations about BP targets in adult renal transplant recipients are coming from a post hoc analysis of a large randomized trial with another primary endpoint. Unless convincing studies on treatment of hypertension after renal transplantation are available, the ESC/ESH Guidelines 2018 should apply for these patients.
Authors: Christos Chatzikyrkou; Jan Menne; Wilfried Gwinner; Bernhard M Schmidt; Frank Lehner; Cornelia Blume; Anke Schwarz; Hermann Haller; Mario Schiffer Journal: J Hypertens Date: 2011-12 Impact factor: 4.844
Authors: Rajiv Saran; Yi Li; Bruce Robinson; Kevin C Abbott; Lawrence Y C Agodoa; John Ayanian; Jennifer Bragg-Gresham; Rajesh Balkrishnan; Joline L T Chen; Elizabeth Cope; Paul W Eggers; Daniel Gillen; Debbie Gipson; Susan M Hailpern; Yoshio N Hall; Kevin He; William Herman; Michael Heung; Richard A Hirth; David Hutton; Steven J Jacobsen; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Yee Lu; Miklos Z Molnar; Hal Morgenstern; Brahmajee Nallamothu; Danh V Nguyen; Ann M O'Hare; Brett Plattner; Ronald Pisoni; Friedrich K Port; Panduranga Rao; Connie M Rhee; Ankit Sakhuja; Douglas E Schaubel; David T Selewski; Vahakn Shahinian; John J Sim; Peter Song; Elani Streja; Manjula Kurella Tamura; Francesca Tentori; Sarah White; Kenneth Woodside; Richard A Hirth Journal: Am J Kidney Dis Date: 2016-03 Impact factor: 8.860
Authors: Arman Faravardeh; Mie Eickhoff; Scott Jackson; Richard Spong; Aleksandra Kukla; Naim Issa; Arthur J Matas; Hassan N Ibrahim Journal: Transplantation Date: 2013-12-27 Impact factor: 4.939
Authors: Arthur D Moes; Dennis A Hesselink; Anton H van den Meiracker; Robert Zietse; Ewout J Hoorn Journal: Am J Kidney Dis Date: 2017-03-01 Impact factor: 8.860
Authors: Matthew R Weir; Ellen D Burgess; James E Cooper; Andrew Z Fenves; David Goldsmith; Dianne McKay; Anita Mehrotra; Mark M Mitsnefes; Domenic A Sica; Sandra J Taler Journal: J Am Soc Nephrol Date: 2015-02-04 Impact factor: 10.121
Authors: Daniel E Weiner; Meyeon Park; Hocine Tighiouart; Alin A Joseph; Myra A Carpenter; Nitender Goyal; Andrew A House; Chi-Yuan Hsu; Joachim H Ix; Paul F Jacques; Clifton E Kew; S Joseph Kim; John W Kusek; Todd E Pesavento; Marc A Pfeffer; Stephen R Smith; Matthew R Weir; Andrew S Levey; Andrew G Bostom Journal: Am J Kidney Dis Date: 2018-07-20 Impact factor: 8.860
Authors: A Hart; J M Smith; M A Skeans; S K Gustafson; A R Wilk; S Castro; J Foutz; J L Wainright; J J Snyder; B L Kasiske; A K Israni Journal: Am J Transplant Date: 2020-01 Impact factor: 8.086
Authors: Ewout J Hoorn; Stephen B Walsh; James A McCormick; Antje Fürstenberg; Chao-Ling Yang; Tom Roeschel; Alexander Paliege; Alexander J Howie; James Conley; Sebastian Bachmann; Robert J Unwin; David H Ellison Journal: Nat Med Date: 2011-10-02 Impact factor: 53.440